E.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Thursday.Shares of e.l.f. Beauty, Inc. (NYSE:ELF) rose sharply during Thursday's session after the company reported better
Jaguar Health, Altamira Therapeutics,Erasca Among Healthcare Movers
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones index closed lower by over 200 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders
Insider Spends US$182k Buying More Shares In Erasca
Investors who take an interest in Erasca, Inc. (NASDAQ:ERAS) should definitely note that the Independent Director, Alexander Casdin, recently paid US$2.27 per share to buy US$182k worth of the stock.
Independent Director of Erasca Picks Up 14% More Stock
Erasca(ERAS.US) Director Buys US$181.92K in Common Stock
$Erasca(ERAS.US)$ Director Casdin Alexander W. purchased 80,000 shares of common stock on May 21, 2024 at an average price of $2.274 for a total value of $181.92K.Source: Announcement What is statemen
Erasca Closes Oversubscribed Share Offering to Raise $184 Million
Erasca (ERAS) said late Tuesday it closed an oversubscribed offering of 99.5 million shares at $1.85 apiece for gross proceeds of $184 million. The completion included the exercise in full by the unde
Press Release: Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc.
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
PDF Version SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializi
Erasca's Strategic Advances and Financial Fortitude Merit a Buy Rating
Erasca Is Maintained at Buy by HC Wainwright & Co.
Erasca Is Maintained at Buy by HC Wainwright & Co.
Erasca Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/20/2024 157.73% HC Wainwright & Co. $8 → $5 Maintains Buy 05/09/2024 312.37% HC Wainwright & Co. → $8 R
Express News | Erasca Inc : Guggenheim Cuts Target Price to $3 From $7
Erasca's Promising Pipeline and Solid Funding Outlook Balanced by Caution: A Hold Rating
Express News | Erasca, Inc. : H.c. Wainwright Cuts Target Price to $5 From $8
Optimistic Outlook for Erasca: Strategic Growth and Financial Prudence
Erasca Inc. Earns Buy Rating: Strategic Acquisitions and Promising Pipeline Positioning
Express News | Erasca Shares Are Trading Higher After the Company Announced That It Entered Into Exclusive License Agreements for Two Preclinical RAS Programs
Erasca Stock Climbs 10% Amid Pipeline Restructuring, Equity Offering
DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Dow futures falling around 10 points on Friday.Shares of DXC Technology Company (NYSE:DXC) fell sharply in today's pre-market trading afte